Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring
- 8 December 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 20 (2) , 254-263
Abstract
Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70–90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia. We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear. Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM). In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM. WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (PPP9/l and lower. Analysis of relapsed cases (14/125) indicated that an abnormal increase or decrease in WT1 expression was associated with a significantly increased risk of relapse (P=0.0006), and this prognostic impact of WT1 was independent of other main risk factors (P=0.0012). In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL. WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL. Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.Keywords
This publication has 54 references indexed in Scilit:
- WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeActa Haematologica, 2004
- WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre studyBritish Journal of Haematology, 2004
- BASP1 Is a Transcriptional Cosuppressor for the Wilms' Tumor Suppressor Protein WT1Molecular and Cellular Biology, 2004
- The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomesHuman Molecular Genetics, 2003
- The complex life of WT1Journal of Cell Science, 2003
- The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemiaBlood, 2003
- WT1-p53 Interactions in Insulin-like Growth Factor-I Receptor Gene RegulationJournal of Biological Chemistry, 2003
- CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaBlood, 2002
- Utility of WT1 as a Reliable Tool for the Detection of Minimal Residual Disease in Children with LeukemiaPediatric and Developmental Pathology, 2002
- Transactivation of the WT1 antisense promoter is unique to the WT1[+/−] isoformFEBS Letters, 1999